Spleen size greater than 9.76 cm may impact the treatment strategy for blunt splenic injury in adults - A retrospective analysis of experience at a tertiary trauma center in Taiwan

Abstract

The present study investigated the impact of splenomegaly on the treatment outcomes of blunt splenic injury patients. All blunt splenic injury patients were enrolled between 2010 and 2018. The exclusion criteria were age less than 18 years, missing data, and splenectomy performed at another hospital. The patients were divided into two groups based on the presence of splenomegaly, defined as a spleen length over 9.76cm on axial computed tomography. The primary outcome was the need for hemostatic interventions. A total of 535 patients were included. Patients with splenomegaly had more high-grade splenic injuries (p=0.007). Hemostatic treatments (p<0.001) and transarterial embolization (p=0.003) were more frequently required for patients with splenomegaly. Multivariate analysis showed that male sex (p=0.023), more packed red blood cell transfusions (p=0.001), splenomegaly (p=0.019) and grade 3-5 splenic injury (p<0.001) were predictors of hemostatic treatment. The failure rate of transarterial embolization was not significantly different between the two groups (p=0.180). The sensitivity and specificity for splenomegaly in predicting hemostatic procedures were 48.8% and 66.5%, respectively. The positive and negative predictive values were 62.8% and 52.9%, respectively. The overall mortality rate was 3.7%. Splenomegaly is an independent predictor for the requirement of hemostatic treatments in blunt splenic injury patients, especially transarterial embolization. Transarterial embolization is as effective for blunt splenic injury patients with splenomegaly as it is for those with a normal spleen.